Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Structure–activity studies on magainins and other host defense peptides

Structure–activity studies on magainins and other host defense peptides Host defense peptides are widely distributed in nature, being found in species from bacteria to humans. The structures of these peptides from insects, horseshoe crabs, frogs, and mammals are known to have the common features of a net cationic charge due to the presence of multiple Arg and Lys residues and in most cases the ability to form amphipathic structures. These properties are important for the mechanism of action that is thougln to be a nonreceptor‐mediated interaction with the anionic phospholipids of the target cell followed by incorporation into the membrane and disruption of the membrane structure. Host defense peptides have been shown to have broad spectrum antimicrobial activity, able to kill most strains of bacteria as well as some fungi, protozoa, and in addition, many types of tumor cells. Specificity for pathogenic cells over host cells is thought to be due to the composition of the cell membranes, with an increased proportion of anionic phospholipids making the pathogen more susceptible and the presence of cholesterol making the host membranes more resistant. Structure–activity relationship studies have been performed on insect cecropins and apidaecins. horseshoe crab tachyplesins and polyphemusins. and the frog magainins. CPFs (caerulein precursor fragments) and PGLa. In general, changes that increased the basicity and stabilized the amphipathic structure have increased the antimicrobial activity: however, as the peptides become more hydrophobic the degree of specificity decreases. One magainin‐2 analogue. MSI‐78. has been developed by Magainin Pharmaceuticals as a topical antiinefective and is presently in clinical trials for the treatment of infected diabetic foot ulcers. © 1994 John Wiley & Sons, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biopolymers Wiley

Structure–activity studies on magainins and other host defense peptides

Maloy, W. Lee; Kari, U. Prasad
Biopolymers , Volume 37 (2) – Jan 1, 1995
Download PDF
18 pages

Loading next page...
 
/lp/wiley/structure-activity-studies-on-magainins-and-other-host-defense-s65gIow78m

References (117)

Publisher
Wiley
Copyright
Copyright © 1995 Wiley Subscription Services
ISSN
0006-3525
eISSN
1097-0282
DOI
10.1002/bip.360370206
pmid
7893944
Publisher site
See Article on Publisher Site

Abstract

Host defense peptides are widely distributed in nature, being found in species from bacteria to humans. The structures of these peptides from insects, horseshoe crabs, frogs, and mammals are known to have the common features of a net cationic charge due to the presence of multiple Arg and Lys residues and in most cases the ability to form amphipathic structures. These properties are important for the mechanism of action that is thougln to be a nonreceptor‐mediated interaction with the anionic phospholipids of the target cell followed by incorporation into the membrane and disruption of the membrane structure. Host defense peptides have been shown to have broad spectrum antimicrobial activity, able to kill most strains of bacteria as well as some fungi, protozoa, and in addition, many types of tumor cells. Specificity for pathogenic cells over host cells is thought to be due to the composition of the cell membranes, with an increased proportion of anionic phospholipids making the pathogen more susceptible and the presence of cholesterol making the host membranes more resistant. Structure–activity relationship studies have been performed on insect cecropins and apidaecins. horseshoe crab tachyplesins and polyphemusins. and the frog magainins. CPFs (caerulein precursor fragments) and PGLa. In general, changes that increased the basicity and stabilized the amphipathic structure have increased the antimicrobial activity: however, as the peptides become more hydrophobic the degree of specificity decreases. One magainin‐2 analogue. MSI‐78. has been developed by Magainin Pharmaceuticals as a topical antiinefective and is presently in clinical trials for the treatment of infected diabetic foot ulcers. © 1994 John Wiley & Sons, Inc.

Journal

Biopolymers – Wiley

Published: Jan 1, 1995

There are no references for this article.